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During the past decade, we have witnessed a major shift in the treatment paradigm for advanced non–small-cell lung cancer (NSCLC). Until the early 2000s, platinum-
doublets remained as the standard of care, and the median survival of advanced NSCLC 
patients was usually 8 to 10 months. The introduction of epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors into the clinic, however, has changed the natural history 
of advanced NSCLC and widely opened a new horizon for precision medicine in lung 
cancer. The history of the development of molecularly targeted therapy in lung cancer, 
however, was not always a success story. In fact, there have been more failures than success 
stories during the past decade.
Sorafenib is the ﬁrst oral multikinase inhibitor that targets Raf1 (C-Raf) kinase (IC50 
of 6 nM).1 Later sorafenib was found to have an expanded activity proﬁle against other 
kinases, for example, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, 
VEGFR-3, platelet-derived growth factor-β, V-Kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog (KIT), Fms-related tyrosine kinase 3 (FLT3), and Ret proto-oncogene 
(RET) as well as wild-type B-Raf and oncogenic B-Raf V600E. These broad target activi-
ties affecting tumor signaling pathway, tumor angiogenesis, and apoptosis and relatively 
favorable toxicity proﬁles led to the development of sorafenib in several human tumor types 
as monotherapy or as combination with other agents. Sorafenib was ﬁrst approved for the 
treatment of advanced renal cell carcinoma in 2005.
The development of sorafenib in NSCLC began in 2004 following encouraging pre-
clinical and early clinical studies. Sorafenib was tested against KRAS-mutated NSCLC, 
and it seemed that this drug could stabilize or decrease tumors with KRAS mutation. In a 
phase II, multicenter single-agent sorafenib study, Blumenschein et al.2 showed a promis-
ing activity of progression-free survival (PFS) of 2.7 months and overall survival (OS) 
of 6.7 months with acceptable toxicity proﬁle in 52 patients with relapsed or refractory 
advanced NSCLC. In E2501, a double-blind randomized discontinuation phase II study of 
sorafenib in previously treated NSCLC patients, Wakelee et al.3 demonstrated a promising 
single agent activity of sorafenib (progression [hazard ratio (HR), 0.51; p = 0.014] and 
overall survival (HR, 0.67; p = 0.117) with manageable toxicities in a heavily pretreated, 
enriched, advanced NSCLC patients.
These promising clinical results prompted a further development of sorafenib 
in advanced NSCLC. In this issue of Journal of Thoracic Oncology, Paz-Ares et al.4 
report the ﬁnal results of the Monotherapy admInistration of Sorafenib in patientS wIth 
nOn-small cell luNg cancer (MISSION) study, a randomized phase III trial comparing 
sorafenib with placebo in patients with relapsed or refractory NSCLC after two or three pre-
vious treatments. The study did not meet the primary end point of increased OS (sorafenib 
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8.2 months versus placebo 8.3 months; HR, 0.99; 95% conﬁ-
dence interval [CI], 0.84–1.17; p = 0.47). The secondary end-
points of median PFS (2.8 versus 1.4 months; HR, 0.61; 95% 
CI, 0.51–1.72; p < 0.0001) and time to progression (TTP) (2.8 
versus 1.4 months; HR, 0.54; 95% CI, 0.45–0.65; p < 0.0001) 
were signiﬁcantly better with sorafenib than with placebo. 
Given that sorafenib has already been approved for renal cell 
carcinoma, hepatocellular carcinoma and differentiated thy-
roid cancer and there is little option for those with advanced 
NSCLC who failed standard of care, this result was quite dis-
appointing. What makes the difference? The common feature 
of the three cancers for which sorafenib is approved is hyper-
vascularity. Sorafenib potently inhibits proangiogenic receptor 
tyrosine kinases (RTKs) such as VEGFR-1/-2/-3, platelet-
derived growth factor receptor-β, and ﬁbroblast growth factor 
receptor 1. This might have led to the successful position-
ing of sorafenib as an anti-angiogenic agent for treatment of 
“unselected” hepatocellular carcinoma (HCC) and renal cell 
carcinoma (RCC) patients through large randomized phase III 
trials, though no single genomic alteration or biomarker to pre-
dict treatment outcome has been discovered yet. In contrast to 
HCC and RCC, cumulative evidence has demonstrated that a 
majority of NSCLC is driven by a speciﬁc genomic alteration. 
Thus, a targeted agent for advanced NSCLC trials should be 
conducted in a more selected patient population.
The pivotal issues for future development of sorafenib 
include the identiﬁcation of appropriate biomarkers for 
patient selection. The traditional approach to the development 
of new therapeutics was largely empirical. This approach used 
to cost a lot of resources and take a long time to complete 
with only marginal or small improvement of clinical beneﬁt. 
The number of patients enrolled in sorafenib trials is almost 
3000, including NExUS (n = 904), ESCAPE (n = 926), E2501 
(n = 342), and MISSION (n = 703). Sorafenib will be marked 
as another major failure in the long list of failed molecular tar-
get agents, which include sunitinib, vandetanib (AZD6474), 
ﬁgitumumab, and more recently tivantinib for advanced 
NSCLC patients. This is absolutely unbearable! How many 
more failures are we supposed to repeat in the development of 
newer therapeutics, especially molecularly targeted agent(s)? 
It is expected that NSCLC patients are likely to be molecularly 
segmented into many smaller subsets in the coming years, and 
the number of target populations in each subset will be getting 
smaller and smaller accordingly.
The MISSION trial was prompted by the two encour-
aging phase II studies, which demonstrated improved dis-
ease control rate or PFS. In retrospect, however, the outcome 
was a statistically signiﬁcant but not a clinically meaning-
ful improvement. There are several precedents of phase III 
trials that failed, despite promising phase II studies, e.g., 
ﬁgitumumab or tivantinib trials. Indeed, we need to observe 
extremely strong signals in phase II studies if we are to 
expect clinically meaningful outcomes to be achieved in 
subsequent phase III studies as was recently highlighted by 
American Society of Clinical Oncology (ASCO).5 How can 
we move forward from yet another failure with a targeted 
agent? When the target population is likely to be a small sub-
set with recurrent but rare driver mutations, one approach 
for the discovery of clinically actionable drivers is genomic 
analysis of exceptional drug responses. For example, Iyer et 
al.6 studied the tumor genome of a patient with metastatic 
bladder cancer who achieved a durable (>2 years) and ongo-
ing complete response to everolimus and identiﬁed Tuberous 
Sclerosis 1 (TSC1) somatic mutations as a potential bio-
marker of the mammalian target of rapamycin complex 1 
(mTORC1)-directed therapies. Imielinski et al.7 used next-
generation sequencing of a patient with a sustained “outlier” 
response to sorafenib and identiﬁed a somatic mutation, 
ARAF S214C. The patient was the last remaining study 
participant receiving sorafenib and 1 of only 9 respond-
ers among 306 evaluable patients on the E2501 study. The 
combined frequency of ARAF and the related kinase RAF1 
was 1% in lung adenocarcinoma. They suggested that ARAF 
and RAF1 mutation could be used to predict the response to 
sorafenib. Both of these studies support the feasibility of this 
approach in the super-responder.
It is intriguing that in an exploratory post hoc analysis, 
OS (13.9 versus 6.5 months; HR, 0.48; 95% CI, 0.30–0.76; 
p = 0.002) and PFS (2.7 versus 1.4 months; HR, 0.27; 95% 
CI, 0.16–0.46; p < 0.001) were signiﬁcantly higher with 
sorafenib than placebo among the 89 patients with EGFR 
mutations. Biomarker treatment interaction analysis for EGFR 
yielded p values of 0.023 for OS and 0.015 for PFS. There 
are minimal data to investigate correlations between EGFR 
mutation status and sorafenib efﬁcacy. In the Biomarker-
Integrated Approaches of Targeted Therapy for Lung Cancer 
Elimination (BATTLE) trial, sorafenib demonstrated clinical 
activity in NSCLC patients, especially with wild-type (WT) 
EGFR and EGFR mutation (MT) predicted worse outcome, 
which does not support the ﬁndings of MISSION trial. OS 
beneﬁt in EGFR-mutated group might have been biased by 
poststudy EGFR tyrosine kinase inhibitor treatment (43% in 
the sorafenib arm versus 18% in the placebo arm) as appro-
priately mentioned by the authors. Extreme caution also 
needs to be exerted in interpreting the observed PFS beneﬁt 
of sorafenib in patients with EGFR mutation because this 
was a post hoc, retrospective analysis in only 47% of all par-
ticipants. In another exploratory analysis of biomarkers, PFS 
was signiﬁcantly longer with sorafenib than placebo irrespec-
tive of KRAS mutation status (MT-KRAS, 2.6/1.7 months; 
HR, 0.46; 95% CI, 0.25–0.82; p = 0.007 versus WT-KRAS, 
2.7/1.4 months; HR, 0.58; 95% CI, 0.45–0.75; p < 0.001). 
OS, however, was similar with either sorafenib or placebo 
in patients with MT-KRAS (6.4/5.1 months; HR, 0.76; 95% 
CI, 0.45–1.26; p = 0.279) and WT-KRAS (11.0/9.1 months; 
HR, 0.79; 95% CI, 0.60–1.03; p = 0.078). Biomarker treat-
ment interaction analysis for KRAS yielded p values of 
0.743 for OS and 0.696 for PFS. In contrast, KRAS muta-
tion was a strong predictive marker of sorafenib in BATTLE 
trial.8,9 Eight-week disease control rate of sorafenib was 79% 
(11/14) in KRAS-mutated patients and 15% (2/13) in wild-
type KRAS patients. Although MISSION failed to show the 
efﬁcacy of sorafenib against KRAS mutated NSCLC, it does 
not necessarily mean all Raf inhibitors are ineffective in 
KRAS mutated NSCLC. There is still room to test Raf inhib-
itors in KRAS-mutated NSCLC. In fact, sorafenib was the 
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most effective agent in the BATTLE trial. In the BATTLE-2 
study, patients are adaptively randomized to four trial arms 
according to KRAS status: erlotinib, erlotinib plus the V-Akt 
murine thymoma viral oncogene homolog 1 (AKT) inhibitor 
MK-2206, MK-2206 plus the mitogen/extracellular signal-
regulated kinase (MEK) inhibitor selumetinib, and sorafenib, 
and the primary objective is 8-week disease-control rate 
(DCR). Results are eagerly awaited.
We do need to raise the bar for clinical trials for 
more meaningful clinical outcomes in the era of precision 
medicine.5 This is especially true when considering the lim-
ited resources but much higher expectations from our patients, 
regulatory authorities, and clinical trial sponsors/investigators. 
Even with a targeted approach, the tumor is so clever that it 
continuously evolves with further genetic alterations to sur-
vive under the pressure of targeted agents, and the disease 
eventually comes back with emergence of acquired resistance 
after a certain period of time. This requires continuous moni-
toring of the disease progress and tailoring of the therapy in an 
appropriate and timely manner.
In this time of precision medicine era, we need to pri-
oritize a clinical trial to seek a larger, clinically meaningful 
gain from a smaller, selected group of patients, which will be 
much faster and less expensive. The initial “Mission” given 
to the ﬁrst RAF inhibitor, unfortunately, has turned out to be 
“Impossible” in advanced NSCLC. However, the ever-grow-
ing wish to conquer KRAS mutations and/or ARAF/RAF1 
mutations in advanced NSCLC should be a new “Mission: 
Possible” for RAF inhibitors in the ﬁght against advanced 
NSCLC and the journey should continue.
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